Skip to Content
Here’s what to ask a doctor about hereditary angioedema

Oritavancin Pregnancy and Breastfeeding Warnings

Oritavancin is also known as: Orbactiv

Oritavancin Pregnancy Warnings

Animal studies have failed to reveal evidence of fetal harm; however, the doses studied were equivalent to 25% of the single 1200 mg clinical dose. There are no controlled data in human pregnancy.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.

US FDA pregnancy category: C

See references

Oritavancin Breastfeeding Warnings

Caution is recommended.

Excretion into human milk: Unknown
Excretion into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Orbactiv (oritavancin)." The Medicines Company, Parsippany, NJ.

References for breastfeeding information

  1. "Product Information. Orbactiv (oritavancin)." The Medicines Company, Parsippany, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide